free webinar on august 16 about drug-resistant tuberculosis

FREE WEBINAR: Implementing a Bedaquiline-Based, Injectable-Free Regimen for Drug-Resistant Tuberculosis August 16, 2018 10 am EDT / 4 pm South Africa / 5 pm KenyaREGISTER HERE We invite you to join a critical discussion on August 16, 2018 at 10 am New York / 4pm South Africa / 5pm Kenya as TAG, TB CAB, and DR-TB STAT host a webinar on Implementing a bedaquiline-based, injectable-free regimen … Continue reading free webinar on august 16 about drug-resistant tuberculosis

mixed tuberculosis infections in gabarone and ghanzi districts, botswana

along with subclinical mycobacterium tuberculosis (mtb), another one of my concerns is mixed mtb infections (simultaneous infection with drug-resistant and drug-susceptible mtb). multiple mtb strains have been detected from the same patient in separate sites (lung vs intrabdominal for example), the same specimen type at different times during treatment, and within the same sample. in gabarone and ghanzi districts, botswana, a recent journal of infectious diseases study by … Continue reading mixed tuberculosis infections in gabarone and ghanzi districts, botswana

four months of rifampin or nine months of isoniazid for latent tuberculosis in adults

i read with interest the recent article in the new england journal of medicine by dick menzies et al, entitled, “four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.” the two regimens were found to be equivalent. a few thoughts are below. this is a nice clinical trial which mirrors our recent clinical experience of preferring rifampin over isoniazid. when … Continue reading four months of rifampin or nine months of isoniazid for latent tuberculosis in adults

Ruvandhi Nathavitharana et Madhukar Pai: Nouvelles stratégies pour les patients hospitalisés avec le VIH et la tuberculose

La réduction de la mortalité liée à la tuberculose, en particulier chez les personnes vivant avec l’infection par le VIH, qui représentent 22% de tous les décès dus à la tuberculose, est une préoccupation mondiale pressante pour la santé. Je suggère de lire le commentaire récent dans le Lancet, écrit par mes bons amis et collègues Drs. Ruvandhi R Nathavitharana de la Harvard Medical School et … Continue reading Ruvandhi Nathavitharana et Madhukar Pai: Nouvelles stratégies pour les patients hospitalisés avec le VIH et la tuberculose

FAST implementation in Bangladesh: high frequency of unsuspected TB justifies challenges of scale-up

Check out our research group’s new paper, where we analyze operational data and discuss the challenges of implementing FAST (Find cases Actively, Separate safely and Treat effectively) as a TB transmission control strategy in Bangladesh. Continue reading FAST implementation in Bangladesh: high frequency of unsuspected TB justifies challenges of scale-up

Soura Bhattacharyya Co-founder & CEO, Lattice Innovations

Today, I am featuring a brief interview with Soura Bhattacharyya, who is doing important work on TB transmission. Where were you born and where did you grow up? I was born in Kolkata and grew up in Delhi. Once I finished high school (in Delhi), I  have been moving somewhat routinely – during undergrad, work, grad school, and thereafter. Post high school, the my longest … Continue reading Soura Bhattacharyya Co-founder & CEO, Lattice Innovations